Theralase Ranked in 2015 Toronto Stock Exchange Venture 50(tm)
February 11, 2015 (Source: Accesswire) — Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that it has been ranked in the Toronto Stock Exchange Venture (“TSXV“) 50(R).
Every year, the TSX Venture 50(R) ranks the strongest companies on the TSXV by share price, trading volume, market capitalization and analyst coverage. The winning companies have seen impressive growth over the past year, offered strong return to their shareholders and are actively traded in the market.
The TSX Venture 50(R) are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – mining, oil & gas, technology & life sciences, diversified industries and clean technology – based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2014.
The ranking is being announced today with the TSXV’s official news release that will reach print, online and broadcast media across Canada and around the world. An additional communication will be sent to analysts and brokers, encompassing broad distribution to the Canadian investment industry. In addition, banner ads will be placed on two key Canadian business sites with high traffic volume; specifically: www.TMX.com , www.TMXmoney.com and finally linking to a dedicated microsite: www.TMX.com/Venture50
Roger Dumoulin-White, President and CEO of Theralase stated that, “On behalf of Theralase, I am honoured to accept the award of being ranked in the prestigious TSX Venture 50(R). The TSX Venture 50(R) represents the cream of the crop of public companies that have shown the commitment to build long term shareholder value through the execution and realization of strategic objectives. In 2015, Theralase will execute on two strategic objectives aimed at increasing long term shareholder value in both our Therapeutic Laser Technology (“TLT“) and Photo Dynamic Therapy (“PDT“) divisions; specifically: the launch of our next generation TLC-2000 therapeutic laser with Cell SensingTM technology that provides higher efficacy than any other therapeutic laser on the market and the commencement of our Health Canada / FDA Phase I / II a clinical trial in humans for Non Muscle Invasive Bladder Cancer (“NMIBC“) aimed at the destruction of bladder cancer.”
About Theralase Technologies Inc.
Founded in 1994, Theralase Technologies Inc. (“Theralase(R)“) (TSXV: TLT) (TLTFF: OTC Pink(R)) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners, including: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been so successful in healing nerve, muscle and joint conditions in clinical practice that Theralase’s scientists and clinicians have now turned their attention to investigating the application of its lasers in the destruction of cancer, using specially designed molecules called Photo Dynamic Compounds (“PDCs“), which are able to localize to the cancer cells and when light activated, destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Raj Shah has been a member of the InvestorIntel.com team for the last nearly 9 years. Recruited from Merrill Lynch, he has over 13 years’ ... <Read more about Raj Shah>